Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
6.66
-0.38 (-5.40%)
At close: Mar 27, 2026, 4:00 PM EDT
6.57
-0.09 (-1.35%)
After-hours: Mar 27, 2026, 7:50 PM EDT
Aligos Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Aligos Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $47, which forecasts a 605.71% increase in the stock price over the next year. The lowest target is $20 and the highest is $70.
Price Target: $47 (+605.71%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aligos Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $60 → $48 | Strong Buy | Initiates | $60 → $48 | +620.72% | Mar 19, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +650.75% | Mar 11, 2026 |
| UBS | UBS | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +200.30% | Jan 7, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +650.75% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +650.75% | Aug 18, 2025 |
Financial Forecast
Revenue This Year
2.30M
from 2.19M
Increased by 4.99%
Revenue Next Year
2.50M
from 2.30M
Increased by 8.89%
EPS This Year
-7.16
from -2.45
EPS Next Year
-6.22
from -7.16
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.7M | 5.1M | |||
| Avg | 2.3M | 2.5M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 116.1% | 124.2% | |||
| Avg | 5.0% | 8.9% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -5.21 | -4.06 | |||
| Avg | -7.16 | -6.22 | |||
| Low | -8.53 | -7.84 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.